GlassScriptPhysician profile
Christopher B Jones
NPI 1700876992
$3,772.46
in general payments reported to CMS, 2019-2025
39 companies · $99.00 in 2025
The $99.00 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $2,348 · 2021: $107 · 2022: $316 · 2023: $130 · 2024: $84.99 · 2025: $99.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $205 · Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $204.99 |
| Food and Beverage | $108.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $2,218.93 | 2020-2023 | |
| Genentech USA, INC. | $153.55 | 2019 | |
| Janssen Biotech, INC. | $149.98 | 2020-2024 | Rybrevant |
| Amgen INC. | $141.09 | 2019-2020 | |
| Seagen INC. | $99.00 | 2025 | |
| Astellas Pharma US INC | $92.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $73.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.06 | 2019-2020 | |
| Gilead Sciences, INC. | $65.52 | 2019-2021 | |
| Celgene Corporation | $43.10 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $42.85 | 2022 | |
| Genzyme Corporation | $42.24 | 2019 | |
| Verastem, INC. | $33.61 | 2019 | |
| Stryker Corporation | $33.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $32.02 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $29.92 | 2022 | |
| Sobi, INC | $27.75 | 2022 | |
| Tesaro, INC. | $26.51 | 2019 | |
| Mylan Institutional INC. | $25.99 | 2022 | |
| Pfizer INC. | $24.80 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $23.15 | 2021 | |
| Grifols USA, LLC | $23.15 | 2020 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Daiichi Sankyo INC. | $20.95 | 2020 | |
| Lilly USA, LLC | $20.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.25 | 2019 | |
| Rigel Pharmaceuticals, INC. | $19.39 | 2019 | |
| Exelixis INC. | $18.96 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $18.52 | 2021 | |
| Eisai INC. | $17.39 | 2022 | |
| Shionogi INC | $17.17 | 2020 | |
| Glaxosmithkline, LLC. | $17.15 | 2020 | |
| Emd Serono, INC. | $16.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.59 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.92 | 2019 | |
| Dova Pharmaceuticals | $14.20 | 2019 | |
| Foundation Medicine, INC. | $13.99 | 2019 | |
| Abbvie INC. | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.